Rucaparib Gets FDA Approval for BRCA-Mutated Ovarian Cancer


The FDA granted accelerated approval to rucaparib (Rubraca), a PARP inhibitor, for the treatment of women with deleterious BRCA mutation-associated ovarian cancer.

The FDA also approved a diagnostic in conjunction with the new agent

The US Food and Drug Administration (FDA) granted accelerated approval to rucaparib (Rubraca), a PARP inhibitor, for the treatment of women with deleterious BRCA mutation-associated ovarian cancer. The approval is for women who have been treated with at least two prior chemotherapy regimens.

“Recurrent ovarian cancer remains one of the most difficult cancers to treat and for so many years, medical advances in this space have been limited,” said Robert L. Coleman, MD, of the MD Anderson Cancer Center in Houston, in a press release from the drug’s developer. Coleman was one of the principal investigators in the trials leading to rucaparib’s approval.

The FDA also approved a diagnostic in conjunction with the new agent, the FoundationFocus CDxBRCA test. This is the first next-generation sequencing test approved by the FDA to test for mutations in ovarian cancer, and can detect both BRCA1 and BRCA2 alterations.

The drug’s approval, after being granted Priority Review status, was based on two multicenter, single-arm, open-label trials, in a total of 106 patients with advanced ovarian cancer whose disease progressed after treatment with at least two prior therapies. The newly approved diagnostic was able to retrospectively verify BRCA mutation status previously determined in 96% of patients for whom a tissue sample was available.

The objective response rate (ORR) with rucaparib was 54%, and the median duration of response in the 57 patients with a response was 9.2 months. Patients deemed platinum-sensitive had an ORR of 66%, compared with only 25% in platinum-resistant patients, and 0% in platinum-refractory patients. There were no differences in response rate between those with BRCA1 and BRCA2 mutations.

A safety cohort of 377 patients showed the most common adverse events included nausea, fatigue, vomiting, anemia, and others. Adverse events led to dose discontinuation in 10% of patients, most frequently from fatigue/asthenia. Two of the 377 patients (0.5%) developed a myelodysplastic syndrome, and two patients in another rucaparib trial developed acute myeloid leukemia. The FDA approval noted that patients should be monitored for hematologic toxicity at baseline and monthly after treatment begins.

“Today’s approval of Rubraca for the treatment of advanced ovarian cancer demonstrates the value of treatment with PARP inhibitors and represents an important advance for women diagnosed with either germline or somatic BRCA-mutated tumors who have been treated with two or more chemotherapies,” Coleman said.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Related Content